CN101584769A - Novel use of esculin and digitalisglycosides eye drops - Google Patents
Novel use of esculin and digitalisglycosides eye drops Download PDFInfo
- Publication number
- CN101584769A CN101584769A CNA2008101123766A CN200810112376A CN101584769A CN 101584769 A CN101584769 A CN 101584769A CN A2008101123766 A CNA2008101123766 A CN A2008101123766A CN 200810112376 A CN200810112376 A CN 200810112376A CN 101584769 A CN101584769 A CN 101584769A
- Authority
- CN
- China
- Prior art keywords
- digitalisglycosides
- esculin
- eye drops
- eye
- diabetic retinopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a novel use of esculin and digitalisglycosides eye drops. Experiments prove that the esculin and digitalisglycosides eye drops have the function of preventing and/or curing diabetic retinopathy so that the esculin and digitalisglycosides eye drops can be used in the preparation of drugs for preventing and/or curing diabetic retinopathy. The invention also provides a suit for preventing and/or curing diabetic retinopathy, which consists of the esculin and digitalisglycosides eye drops and a massager. The esculin and digitalisglycosides eye drops can effectively prevent the diabetic retinopathy when used by diabetics in early stage together with the massager and can effectively control the deterioration of diseases of the patients with diabetic retinopathy together with point massage as well as restore part of the sight of the patients to obviously improve the conditions of the patients after long term use.
Description
Technical field
The present invention relates to the new purposes of esculin and digitalisglycosides eye drops.
Background technology
Data show, the retinopathy that diabetes caused is the arch-criminal who causes people to lose one's sight, about 47.3% blind case is that retinopathy causes.
Diabetes are metabolic diseases of a kind of complexity, often cause the extensive infringement of the many tissues of whole body, organ, and wherein diabetic renal papillary necrosis is exactly more common a kind of eye secondary lesion.According to statistics, in diabetics, have 10% patient just retinopathy can take place in 5～9 years approximately after morbidity, about 50% patient was taken place after 15 years, then had 80%～90% patient retinopathy to occur after 25 years.
Most patients with diabetic retinopathy are at the pathological changes initial stage, the general no conscious sympton of eye, but along with the development of pathological changes, visual deterioration in various degree can appear.If macular area is got involved, patient has symptoms such as visual field central authorities shadow, central vision decline and metamorphopsia.When the little angiorrhexis of retina, a small amount of hemorrhage vitreous body that enters, the patient understands consciously has shadow to wave at the moment.When the new vessels vitreous chamber of bleeding profusely, patient's vision can heavily be lost, and only deposits light sensation.Retinal vascular occlusion beyond the macular area, or proliferative retinopathy can cause detachment of retina, and it is damaged that the corresponding site larger area appears in the patient visual field.
Esculin and digitalisglycosides eye drops is the compound preparation that is mixed and made into by Chinese medicine Digitalis extract and esculetin glucoside, is the local topical medicine of eye.Esculin and digitalisglycosides eye drops is at first to succeed in developing (pharmaceutical factory, Turin is looked by Germany) abroad, and indication abroad is: 1) the irritated conjunctivitis that causes of prevention or treatment; 2) alleviate fast eye red, swollen, hot, bitterly, the above-mentioned symptom of scratching where it itches and burning and causing; 3) prevention or treatment microgranule conjunctivitis, optic neuritis, retinitis; 4) prevent or treat non-infectious and allergic eye inflammation.At present esculin and digitalisglycosides eye drops is domestic also an import, and the indication of imported product is: fundus macular degeneration; All types of eyestrain comprise eye muscle, nerve and adaptive.
Summary of the invention
A kind of new purposes that the purpose of this invention is to provide esculin and digitalisglycosides eye drops.
The invention provides esculin and digitalisglycosides eye drops and prevent and/or treat application in the diabetic renal papillary necrosis medicine in preparation.
The present invention also provides a kind of suit that prevents and/or treats diabetic renal papillary necrosis, and described suit is made up of esculin and digitalisglycosides eye drops and masseur.
The present invention by evidence esculin and digitalisglycosides eye drops have the effect that prevents and/or treats diabetic renal papillary necrosis.Esculin and digitalisglycosides eye drops is for the diabetes early stage patient, effectively the prevent diabetes retinopathy; For the patient who diabetic renal papillary necrosis occurs, sb.'s illness took a turn for the worse for may command, and life-time service can partly recover vision, and the state of an illness is obviously alleviated.Prevent and/or treat diabetic renal papillary necrosis with the suit of forming by esculin and digitalisglycosides eye drops and masseur of the present invention, can obtain than esculin and digitalisglycosides eye drops better therapeutic.
Following embodiment is convenient to understand better the present invention, but does not limit the present invention.
The specific embodiment
In following examples, the evaluation criterion of diabetic renal papillary necrosis is as follows:
Change according to the optical fundus, diabetic renal papillary necrosis be divided into for six phases:
I (1): retina has microaneurysm or and little petechia is arranged.
(+) minute quantity, easily number; (++) is more, is difficult for number.
II (2): retina has HUANGBAI(sic) " rigid oozing out " or and ecchymosis is arranged.
(+) minute quantity, easily number; (++) is more, is difficult for number.
III (3): retina adularescent " soft oozing out " or and ecchymosis arranged.
(+) minute quantity, easily number; (++) is more, is difficult for the number proliferous type.
IV (4): retina has new vessels and/or vitreous hemorrhage.
V (5): retina has new vessels and fiber propagation.
VI (6): retina has new vessels and fiber to breed concurrent existing network film disengaging.
Wherein I, II, III phase are referred to as simple retinopathy, IV, V, VI phase are referred to as proliferative diabetic retinopathy, show as retina microangioma, the retinal hemorrhage speckle, soft and rigid retinal exudates, arteria retina pathological changes and retinal vein pathological changes.So-called proliferative diabetic retinopathy refers to that pathological changes has at least part to extend inwardly past internal limiting membrane, shows as new vessels, fibroid propagation and traction detachment of retina.
Experimental technique among the following embodiment if no special instructions, is conventional method.
The curative effect checking of embodiment 1, esculin and digitalisglycosides eye drops prevent diabetes retinopathy
1, makes diabetes rat model
(STZ) uses 0.1mol/L with streptozotocin, and the citrate buffer solution dissolving of pH4.2 is mixed with 2% STZ solution.60 of SD rats (purchasing the Experimental Animal Center in Liaoning Medical University) are by 65mg/kg body weight tail vein injection streptozotocin (the injection process Chinese medicine places ice bath).Injection back 48h detects glucose in urine and blood glucose, and glucose in urine exists +++more than, blood glucose is higher than 16.65m mol/L for becoming the mould standard.
Rat behind the Cheng Mo, blood glucose, glucose in urine all remain on higher level, and prolong with the course of disease and to increase, and polydipsia, polyphagia, polyuria all occur simultaneously, become thin, performance such as movable minimizing.
2, the compliance test result of esculin and digitalisglycosides eye drops prevent diabetes retinopathy
Become mould after 2 weeks, select blood glucose value to be used for experiment 30 of the rats of 350～550mgdl.Laboratory animal is fed the standardization feeding room in animal center, and raises with the standard particle feedstuff.The feeding room condition: room ventilation is good, relative humidity 40%～70%, 18～22 ℃ of room temperatures.
Divide 3 groups at random with 30 diabetes rats, 10 every group.3 groups of rats carry out administration respectively, and are specific as follows:
First group (blank group): drip normal saline, every day three times, each one, splash into (the near ear side tail of the eye) in the conjunctival sac;
Second group (positive group): drip esculin and digitalisglycosides eye drops (Germany looks pharmaceutical factory, Turin and produces, lot number 070314), every day three times, each one, splash into (the near ear side tail of the eye) in the conjunctival sac;
The 3rd group (treatment group): (Germany looks pharmaceutical factory, Turin and produces to drip esculin and digitalisglycosides eye drops, lot number 070314), every day three times, each one, splash into (the near ear side tail of the eye) in the conjunctival sac, give medicine at every turn and use the Zanzhu of massage device eye, chengqi, the sun, four acupuncture points of Yuyao, each acupoint massage 30～60 seconds in order.
20 weeks of successive administration, check retina, according to standard the retinopathy situation to be made an appraisal, 3 groups of rat retina pathological changes situations see Table 1.
Table 1 is the retinopathy situation of rat on the same group not
The result shows, becomes mould after 20 weeks, and blank group diabetic renal papillary necrosis is very serious, and 20% is in (6) phase, and 40% is in (5) phase, and 30% is in (4) phase, and 10% is in (3) phase; The positive group course of disease is alleviated to some extent, and 30% is in (3) phase, and 50% is in (2) phase, and 20% is in (1) phase; Treatment group effect is best, and 20% is in (2) phase, and 50% is in (1) phase, and 30% does not see diabetic renal papillary necrosis.Experimental result shows that esculin and digitalisglycosides eye drops is the prevent diabetes retinopathy obviously, massages then better effects if of eye Zanzhu, chengqi, the sun, four acupuncture points of Yuyao during use successively.
The curative effect checking that embodiment 2 esculin and digitalisglycosides eye drops treatment of diabetic retinopathy become
1, makes diabetes rat model
Step 1 with embodiment 1.
2, the compliance test result of esculin and digitalisglycosides eye drops treatment of diabetic retinopathy change
Become the retina of 12 week of mould back observation rat, the selection retinopathy is in (4) phase and 30 close of rats of lesion degree are used for experiment.Laboratory animal is fed the standardization feeding room in animal center, and raises with the standard particle feedstuff.Room ventilation is good, relative humidity 40%～70%, 18～22 ℃ of room temperatures.
Divide 3 groups at random with 30 diabetic renal papillary necrosis rats, 10 every group.3 groups of rats carry out administration respectively, and are specific as follows:
First group (blank group): drip normal saline, every day three times, each one, splash into (the near ear side tail of the eye) in the conjunctival sac;
Second group (positive group): drip esculin and digitalisglycosides eye drops (Germany looks pharmaceutical factory, Turin and produces, lot number 070314), every day three times, each one, splash into (the near ear side tail of the eye) in the conjunctival sac;
The 3rd group (treatment group): (Germany looks pharmaceutical factory, Turin and produces to drip esculin and digitalisglycosides eye drops, lot number 070314), every day three times, each one, splash into (the near ear side tail of the eye) in the conjunctival sac, give medicine at every turn and use the Zanzhu of massage device eye, chengqi, the sun, four acupuncture points of Yuyao, each acupoint massage 30～60 seconds in order.
10 weeks of successive administration, observe retina with ophthalmofundoscope, according to standard the retinopathy situation to be made an appraisal, 3 groups of rat retina pathological changes situations see Table 2.
Table 2 is the retinopathy situation of rat on the same group not
The result shows, treated for 10 weeks after, blank group 40% is in (6) phase, 60% is in (5) phase; Positive group 50% is in (3) phase, and 50% is in (2) phase; Treatment group 30% is in (2) phase, and 70% is in (1) phase.Experimental result shows that esculin and digitalisglycosides eye drops is the diabetes-alleviating retinopathy obviously, massages then better efficacy of eye Zanzhu, chengqi, the sun, four acupuncture points of Yuyao during use successively.
Claims (2)
1, esculin and digitalisglycosides eye drops prevents and/or treats application in the diabetic renal papillary necrosis medicine in preparation.
2, a kind of suit that prevents and/or treats diabetic renal papillary necrosis is made up of esculin and digitalisglycosides eye drops and masseur.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101123766A CN101584769A (en) | 2008-05-22 | 2008-05-22 | Novel use of esculin and digitalisglycosides eye drops |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101123766A CN101584769A (en) | 2008-05-22 | 2008-05-22 | Novel use of esculin and digitalisglycosides eye drops |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101584769A true CN101584769A (en) | 2009-11-25 |
Family
ID=41369338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101123766A Pending CN101584769A (en) | 2008-05-22 | 2008-05-22 | Novel use of esculin and digitalisglycosides eye drops |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101584769A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101874848B (en) * | 2009-12-08 | 2012-07-04 | 于洪儒 | Digitalis extract, preparation method and application thereof |
-
2008
- 2008-05-22 CN CNA2008101123766A patent/CN101584769A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101874848B (en) * | 2009-12-08 | 2012-07-04 | 于洪儒 | Digitalis extract, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101716214B (en) | Medical composition containing dandelion extract as well as novel application and preparation method thereof | |
| CN102362924B (en) | Medicinal composition for treating ophthalmic diseases and preparation method thereof | |
| DE60130872T2 (en) | METHOD AND MEANS FOR TREATING AND PREVENTING DISEASES OF THE REAR EYES CHAMBER | |
| CN108904633A (en) | A kind of eye ointment and preparation method thereof improving eyesight | |
| CN108186733A (en) | A kind of pharmaceutical gel patch and its preparation method and application | |
| CN104474009A (en) | Eye cleaning liquid and preparation method thereof | |
| CN102526171B (en) | Eye health care product capable of preventing and delaying senile macular degeneration and manufacture method | |
| CN105188702B (en) | Using Dipyridamole for treating the composition of disease of eye | |
| CN101584769A (en) | Novel use of esculin and digitalisglycosides eye drops | |
| CN103720857A (en) | Traditional Chinese medicinal preparation for treating fundus macular oedema lesion | |
| CN102512467A (en) | Ophthalmic preparation of panax notoginseng saponins and preparation method thereof | |
| CN101361892A (en) | Traditional Chinese medicine formulation for treating cataract and preparation method thereof | |
| CN105232640A (en) | Method of using cistanche tubulosa extract for preparing drugs or food to protect eye cells | |
| JP4921165B2 (en) | Flupirtine formulation for the treatment of neurodegenerative diseases of the visual organs and diabetes mellitus | |
| Nebbioso et al. | Forskolin and rutin prevent intraocular pressure spikes after Nd: YAG laser iridotomy | |
| CN100423731C (en) | Eye brightening eye washing liquid and its preparation method | |
| CN105769920A (en) | Pearl clear-sighted eye drops and preparation method | |
| CN103860731A (en) | Pure traditional Chinese medicine preparation for treating eye disease | |
| CN116785290B (en) | Application of benzphetamine and isomer thereof in preparation of ophthalmic preparation | |
| CN103550455B (en) | Traditional Chinese medicine for treating glaucoma | |
| US12005093B2 (en) | Traditional chinese medicine eye drops and the preparation method thereof | |
| CN113318121B (en) | Medicine for treating diabetic retinopathy and preparation method thereof | |
| CN1306938C (en) | Combination for local use for preventing anti treating ocular disease | |
| RU2494735C1 (en) | Method of treating corneal ulcers | |
| CN105920060A (en) | Medicine composition containing iodized lecithin and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20091125 |